Huh C G, Håkansson K, Nathanson C M, Thorgeirsson U P, Jonsson N, Grubb A, Abrahamson M, Karlsson S
Molecular and Medical Genetics Section, NCI, National Institutes of Health, Bethesda, MD 20892, USA.
Mol Pathol. 1999 Dec;52(6):332-40. doi: 10.1136/mp.52.6.332.
Increased or altered activities of cysteine proteases have been implicated in serious human disorders such as cancer, rheumatoid arthritis, sepsis, and osteoporosis. To improve the current knowledge of the regulatory role of a major mammalian cysteine protease inhibitor, cystatin C, in such disease processes, a cystatin C deficient mouse was generated and characterized.
The mouse cystatin C gene was inactivated by insertion of a bacterial neo gene through homologous recombination in 129/Sv embryonic stem cells. Embryonic stem cell clones were injected into C57BL/6J blastocysts followed by injection of the blastocysts into pseudopregnant female mice. F1 offspring with agouti coat colour after mating of chimaeric males with C57BL/6J females were examined by DNA analysis, and mice carrying the targeted mutation were intercrossed to obtain homozygous cystatin C deficient (CysC-/-) mice. To study the role of cysteine proteases and their inhibitors in metastasis, the spread of B16-F10 melanoma cells in CysC-/- and wild-type mice was compared. Analysis of the formation of remote metastases was carried out by intravenous injection of beta-galactosidase transfected B16-F10 cells and subsequent determination of cancer cell colonies in the lungs.
Cystatin C deficient mice were fertile and showed no gross pathological abnormality up to 6 months of age. Compared with wild-type mice, seven times fewer large metastatic colonies were counted by means of a dissecting microscope in CysC-/- mice two weeks after tail vein injection of B16-F10 cells. At all of eight time points from 15 minutes to two weeks after intravenous injection of tumour cells, the CysC-/- mice had significantly fewer lung metastases. The observed differences were smaller when beta-galactosidase transfected cells were used to allow counting of small colonies. Subcutaneous and intracerebral tumour growth was not different in the CysC-/- mice.
Cystatin C concentrations in vivo might influence metastasis in some tissues. The decreased metastatic spread of B16-F10 cells in CysC-/- mice is the result of both reduced seeding and reduced growth of tumour cells in their lungs.
半胱氨酸蛋白酶活性的增加或改变与癌症、类风湿性关节炎、败血症和骨质疏松症等严重人类疾病有关。为了增进对主要哺乳动物半胱氨酸蛋白酶抑制剂胱抑素C在这些疾病过程中调节作用的现有认识,我们培育并鉴定了胱抑素C缺陷小鼠。
通过在129/Sv胚胎干细胞中进行同源重组插入细菌新霉素基因,使小鼠胱抑素C基因失活。将胚胎干细胞克隆注射到C57BL/6J囊胚中,然后将囊胚注射到假孕雌性小鼠体内。将嵌合雄性小鼠与C57BL/6J雌性小鼠交配后,对具有刺鼠毛色的F1后代进行DNA分析,并将携带靶向突变的小鼠进行杂交,以获得纯合胱抑素C缺陷(CysC-/-)小鼠。为了研究半胱氨酸蛋白酶及其抑制剂在转移中的作用,比较了B16-F10黑色素瘤细胞在CysC-/-小鼠和野生型小鼠中的扩散情况。通过静脉注射β-半乳糖苷酶转染的B16-F10细胞并随后测定肺中的癌细胞集落,来分析远处转移的形成。
胱抑素C缺陷小鼠可育,在6个月龄前未表现出明显的病理异常。与野生型小鼠相比,在尾静脉注射B16-F10细胞两周后,通过解剖显微镜在CysC-/-小鼠中计数到的大转移集落数量减少了七倍。在静脉注射肿瘤细胞后15分钟至两周的所有八个时间点,CysC-/-小鼠的肺转移灶明显更少。当使用β-半乳糖苷酶转染的细胞来计数小集落时,观察到的差异较小。CysC-/-小鼠的皮下和脑内肿瘤生长没有差异。
体内胱抑素C浓度可能会影响某些组织中的转移。CysC-/-小鼠中B16-F10细胞转移扩散减少是肿瘤细胞在其肺中播种减少和生长减少的结果。